Browse by author
Lookup NU author(s): Dr Sarah Johnson, Dr Steven Hardy, Dr David Bourn, Dr Ujjal Mallick, Dr Petros Perros
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
BackgroundBRAF V600E mutation has been reported to show a high specificity for papillary thyroid carcinoma (PTC). Using this marker to upgrade indeterminate' or suspicious' thyroid fine needle aspiration (FNA) cytology to malignant' could potentially allow one-stage therapeutic total thyroidectomy.MethodsFor a 14-month period, FNA cytology specimens in the Thy3-5 categories, which are the UK equivalents of indeterminate (Thy3a, atypical; Thy3f, follicular), suspicious for malignancy (Thy4) and malignant (Thy5) in the Bethesda System, underwent BRAF mutation testing by melt curve analysis. The results were correlated with histology.ResultsWe tested 123 cytology specimens of which 12 (9.8%) failed. The BRAF mutation rate in the remainder was 16.2% (18/111), with 93 showing the wild-type. Seventeen mutations were V600E and one was non-V600E. The rate of mutation increased significantly (P<0.0001 if Thy3a and Thy3f were combined) with the cytology category: 1/42 Thy3a (2.4%), 1/36 Thy3f (2.8%), 4/15 Thy4 (26.7%), 12/18 Thy5 (66.7%). All BRAF mutations correlated with PTC on histology, except for one recurrent PTC without histology. One mutation-positive case with Thy3a cytology showed the target lesion to be a 10-mm follicular adenoma on histology with an immediately adjacent 4-mm micro-PTC, in a patient who did not require total thyroidectomy.ConclusionBRAF mutational analysis by melt curve analysis is feasible in routine thyroid cytology, and in our series had a 100% specificity for PTC in subsequent histology. The application of BRAF analysis could be useful for indeterminate cytology, but we suggest that it would be most appropriate and cost-effective for Thy4/suspicious cases, for which it could enable one-stage therapeutic surgery in the context of multidisciplinary discussion. In contrast, the sensitivity is low and there is no role for avoiding diagnostic thyroid surgery if wild-type BRAF is found.
Author(s): Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P
Publication type: Article
Publication status: Published
Journal: Cytopathology
Year: 2014
Volume: 25
Issue: 3
Pages: 146-154
Print publication date: 01/06/2014
Online publication date: 12/01/2014
Acceptance date: 08/10/2013
ISSN (print): 0956-5507
ISSN (electronic): 1365-2303
Publisher: Wiley-Blackwell
URL: http://dx.doi.org/10.1111/cyt.12125
DOI: 10.1111/cyt.12125
Altmetrics provided by Altmetric
